Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
ELVN notice of proposed sale of Common Stock under Rule 144 by selling holders, reporting broker allocations and recent dispositions.
The filing lists a proposed sale of 833,800 shares (dated 02/23/2023), broker entries showing 787,024 and 46,776 shares, and a recent reported sale of 272,322 shares on 06/15/2026 for $12,259,936.44. The excerpt shows total shares outstanding as 69,822,989 as of 06/22/2026.
The Biotech Growth Trust PLC reported proposed sales of Common Stock under a Form 144. The filing lists proposed brokered sales of 29,385 shares through Jefferies LLC and 1,747 shares through Morgan Stanley & Co. LLC. The filing also records a prior sale of 10,243 shares on 06/15/2026 for $461,139.86. Shares outstanding are shown as 69,822,989 as of 06/22/2026.
Enliven Therapeutics, Inc. chief financial officer Benjamin Hohl exercised stock options and sold shares of common stock in coordinated transactions. He exercised options for 6,018 shares at an exercise price of $2.48 per share and then sold 6,018 shares in several open-market trades on June 17, 2026 at weighted average prices between $42.79 and $44.75 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Hohl directly holds 51,000 shares of Enliven common stock, indicating he retains a meaningful equity stake in the company.
Enliven Therapeutics, Inc. chief medical officer Helen Louise Collins reported a mix of option exercise and share sales in the company’s stock. On June 17, 2026, she exercised options for 5,000 shares of common stock at a strike price of $2.48 per share, then sold a total of 5,000 shares in three open-market transactions at weighted average prices of $42.8270, $43.8701 and $44.7430 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the transactions, she holds 25,000 shares of common stock directly and 121,268 stock options.
Enliven Therapeutics disclosed that Polar Capital entities beneficially own 5,056,807 shares of Common Stock, representing 8.46% of the class. The filing cites 60,904,946 shares outstanding as reported in the issuer's Form 10-Q on May 7, 2026. The Schedule 13G/A is signed on June 19, 2026 by Nicholas Farren.
Enliven Therapeutics, Inc. disclosed that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. OrbiMed-related holders sold 272,322 shares at $45.02 per share and an additional 9,086 shares at the same price. After these transactions, the reporting entities’ indirect holdings reported in this filing were 7,388,902 shares and 245,728 shares, respectively. Footnotes explain that OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP hold the shares of record, and OrbiMed-affiliated general partners and OrbiMed Advisors may be deemed to share voting and investment power while disclaiming beneficial ownership beyond any pecuniary interest.
OrbiMed entities filed Amendment No. 4 to update their ownership in Enliven Therapeutics, Inc. common stock. The filing reports that OrbiMed Advisors LLC may be deemed to beneficially own 7,634,630 shares, representing 10.93% of Enliven’s outstanding common stock.
This percentage is based on 69,822,929 shares outstanding, as stated in Enliven’s Rule 424(b)(5) prospectus. The amendment notes that, due to recent transactions and an increase in shares outstanding, the OrbiMed group’s beneficial ownership decreased by more than 1%.
The position is held through several investment vehicles: OrbiMed Private Investments VII, LP with 7,388,902 shares (10.58%), OrbiMed Genesis Master Fund, L.P. with 245,728 shares (0.35%), and The Biotech Growth Trust PLC with 31,132 shares (0.04%). OrbiMed-related entities share or exercise voting and investment power over these holdings, while individual OrbiMed principals disclaim beneficial ownership. The group states it may buy more, hold, or sell shares over time but has no specific corporate action plans.
Enliven Therapeutics filed a Form 144 reporting the proposed sale of 18,054 shares of Common Stock through Jefferies LLC, dated 06/17/2026. The notice lists three lots tied to option exercises: 7,090, 3,000, and 7,964 shares with exercise dates shown as 08/09/2022, 12/13/2024, and 03/04/2025, respectively.
The filing identifies Jefferies LLC at 520 Madison Ave as the broker-dealer and shows an aggregate value field of $768,197.70 on the cover line. The filing is a routine Section 16 disposition notice for resale of shares previously acquired by option exercise.